Journals / Türk Nöroşirürji Dergsi / 2017 / Cilt: 27 - Sayı: 2

Neurocutaneous Syndromes-Phacomatoses

Nörokütanöz Sendromlar-Fakomatozlar

Pages
131–136
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Neurocutaneous syndromes (phacomatoses) result in cancer predisposition and, therefore, are important diseases in daily neurooncological practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neurocutaneus syndromes are genetically inherited diseases that involve multiple tissues of ectodermal origin.
📊
Key Findings & Data:Up to 67 of these syndromes, which are associated with tumors ranging from hamartomas to malignant carcinomas, have been described.
💡
Conclusion & Impact:Neurocutaneous syndromes (phacomatoses) result in cancer predisposition and, therefore, are important diseases in daily neurooncological practice.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neurocutaneus syndromes are genetically inherited diseases that involve multiple tissues of ectodermal origin. Due to their skin manifestations, these syndromes are also called phacomatoses. Up to 67 of these syndromes, which are associated with tumors ranging from hamartomas to malignant carcinomas, have been described. Therefore, they are a very important issue in neurooncology. The aim of this paper is to summarize the clinical outlines of the most common neurocutaneus syndromes in the light of recent developments. Clinical outlines of the six most common neurocutaneous syndromes (Neurofibromatosis type I, Neurofibromatosis type II, Tuberous sclerosis, Sturge-Weber syndrome, Von Hippel Lindau syndrome and Ataxia-telengiectasia) will be discussed in detail. Neurocutaneous syndromes (phacomatoses) result in cancer predisposition and, therefore, are important diseases in daily neurooncological practice.

Özet

Nörokütanöz sendromlar ektodermal kökenli dokuları etkileyen, genetik geçişli hastalıklardır. Cilt bulguları nedeniyle "fakomatozlar" olarak da isimlendirilirler. Bugüne kadar 67 tanesi tanımlanmış olan bu sendromlar kanser yatkınlığı oluşturdukları ve sık olarak hamartomlardan malign tümörlere uzanan geniş bir yelpazede tümörlerin oluşumuna neden oldukları için nöroonkolojide son derece önemlidirler. Bu yazının amacı sık görülen nörokütanöz sendromların klinik özelliklerini güncel gelişmeler ışığında yeniden özetlemektir. Sık görülen 6 nörokütanöz sendrom (Nörofibromatoz tip I, Nörofibromatoz tip II, Tüberoskleroz, Sturge-Weber sendromu, Von Hippel Lindau sendromu, Ataksi-telenjiektazi) klinik özellikleri açısından ana hatları ile sunulacaktır. Nörokütanöz sendromlar (Fakomatozlar) kanser yatkınlığına yol açtıkları için klinik nöroonkolojide önemli hastalıklardır.

🔖

Cite This Article

BÖRCEK, A. Ö., BULDUK, E. B. (2022). Neurocutaneous Syndromes-Phacomatoses. Türk Nöroşirürji Dergsi, Cilt: 27 - Sayı: 2, 131–136. https://ajindex.com/articles/637403

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Arslan U, Dürük K: Fakomatozlar. T Klin Oft 12(3):170-180, 2003 2. Bayraklı F, Çankaya T, Bayri Y, Güney İ: Von Hippel-Lindau hastalığının moleküler genetiği. Türk Nöroşir Derg 19(1):36-40, 2009 3. Çalışkaneller T, Özdemir Ö, Caner H, Altınörs N: Bir tüberoskleroz hastasında serebellar kalsifikasyon: Olgu sunumu. Türk Nöroşir Derg 18(2):134-137, 2008 4. Daras M, Kaley TJ: Benign brain tumors and tumors associated with phakomatoses. Continuum (Minneap Minn) 21(2 Neurooncology): 397-414, 2015 5. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, Friedrich RE, Kurtz A: Imatinibmesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98(1):11-19, 2010 6. Erol İ, Savaş T, Şekerci S, Yazıcı N, Erbay A, Demir Ş, Alkan Ö: Tüberoskleroz kompleksi; tek merkez deneyimi. Türk Ped Arş 50:51-60, 2015 7. Feletti A, Anglani M, Scarpa B, Schiavi F, Boaretto F, Zovato S, Taschin E, Gardi M, Zanoletti E, Piermarocchi S, Murgia A, Pavesi G, Opocher G: Von Hippel-Lindau disease: An evaluation of natural history and functional disability. Neuro Oncol 18(7):1011-1020, 2016 8. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59(3):490-498, 2006 9. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Pan D: Tsc tumour suppressor proteins antagonize aminoacid-TOR signalling. Nat Cell Biol 4(9):699-704, 2002 10. Greenberg MS: Neurocutaneous disorders. Greenberg MS. Handbook of Neurosurgery. 7th ed. New York: Thieme Medical Publishers, 2010:722-724 11. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Viskochil D: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51-57, 1997 12. Halefoğlu AM, Arık ZB, Özel A, Yıldız E, Çalışkan CK: Komplike bir von Hippel-Lindau olgusu. Turkiye Klinikleri J Med Sci 25(5):753-757, 2005 13. Haslam R: Neurocutaneous syndromes. In: Nelson WE, Behrman RE, Kliegman RM, Arvin AM (eds). Nelson Textbook of Pediatrics, 15th ed. Philadelphia: WB Saunders, 1996:1707- 1709 14. Işık N: Fakomatozlar, Nörofibromatozis, Tuberosklerosis, VonHippel Lindau. Baykaner K, Erşahin Y, Mutluer S, Özek M (eds). Pediatrik Nöroşirürji. Ankara: Buluş Tasarım, 2014:529- 549 15. Kaelin WG: The Von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10(18):6290S-6295S, 2004 16. Kerriso